Simulations Plus, Inc. develops and markets modeling and simulation software for the pharmaceutical and biotechnology industries. Key products such as GastroPlus predict pharmacokinetics and pharmacodynamics, ADMET Predictor uses AI to forecast ADMET properties from molecular structures, and MonolixSuite supports population modeling and clinical data analysis. Clients use the tools and accompanying services to improve decision-making throughout drug discovery, development, and regulatory processes.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 20.4 | — | -67.3 | — |
| Q3 2025 | 17.5 | — | -0.7 | — |
| Q4 2025 | 18.4 | — | 0.7 | — |
| Q1 2026 | 24.3 | — | 4.5 | — |
| Q2 2026 | 21.9 | 7.5% | 3.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: HCM IV Acquisition Corp. (HACQ), Shoe Station Group Inc. (SHOE), BRBI BR Partners S.A. (BRBI), Advantage Solutions Inc. (ADV), Zura Bio Limited (ZURA), GigCapital8 Corp. (GIW)